MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
112.88%
Quick Ratio
112.88%
Cash Ratio
93.61%
Debt to Asset Ratio
65.04%
Unit: Thousand (K) dollars
Assets Breakdown
    • In-process research and developm...
    • Cash and cash equivalents
    • Right of use asset
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Non-current contingent considera...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
11,337
14,431
13,056
7,528
Tax credit receivable
1,681
1,696
3,351
1,721
Prepaid expenses and other current assets
653
630
1,060
654
Total current assets
13,671
16,757
17,467
9,903
Property and equipment, net
173
194
222
249
Restricted cash
44
45
46
46
Right of use asset
1,825
1,946
803
942
In-process research and development
19,064
19,225
19,619
19,614
Deposits and other assets
80
81
82
82
Total assets
34,857
38,248
38,239
30,836
Accounts payable
984
608
1,014
795
Accrued expenses
6,418
6,220
6,276
7,685
Contingent consideration, current portion
2,650
1,193
-
-
Accrued employee benefits
290
267
443
747
Deferred research and development tax credit-current portion
1,210
1,431
1,675
1,101
Loans payable-current
34
35
57
57
Operating lease liability-current portion
525
510
549
618
Total current liabilities
12,111
10,264
10,014
11,003
Non-current contingent consideration
7,169
8,838
10,004
10,793
Loan payable - non-current
1,620
1,626
1,671
1,654
Non-current deferred research and development tax credit
396
599
815
215
Non-current operating lease liability
1,374
1,522
352
433
Total liabilities
22,670
22,849
22,856
24,098
Common stock, 0.001 par value 350,000,000 shares authorized, 45,921,478 issued and 45,892,668 outstanding at june 30, 2026 and 35,717,159 issued and 35,688,350 outstanding at december 31, 2025
45
45
34
9
Additional paid-in capital
376,154
376,019
373,592
362,968
Treasury stock at cost, 28,810 shares at june 30, 2026 and at december 31, 2025
288
288
288
288
Accumulated other comprehensive loss
247
377
755
763
Accumulated deficit
-363,971
-360,754
-358,710
-356,714
Total stockholders' equity
12,187
15,399
15,383
6,738
Total liabilities and stockholders' equity
34,857
38,248
38,239
30,836
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$11,337K (-6.46%↓ Y/Y)Tax creditreceivable$1,681K (-2.38%↓ Y/Y)Prepaid expenses andother current assets$653K (-27.52%↓ Y/Y)In-process research anddevelopment$19,064K (-2.85%↓ Y/Y)Total current assets$13,671K (-7.27%↓ Y/Y)Right of use asset$1,825K (69.45%↑ Y/Y)Property and equipment,net$173K (-32.95%↓ Y/Y)Deposits and other assets$80K (-2.44%↓ Y/Y)Restricted cash$44K (-4.35%↓ Y/Y)Total assets$34,857K (-2.72%↓ Y/Y)Total liabilities andstockholders' equity$34,857K (-2.72%↓ Y/Y)Total liabilities$22,670K (-10.06%↓ Y/Y)Total stockholders'equity$12,187K (14.72%↑ Y/Y)Accumulated deficit-$363,971K (-3.30%↓ Y/Y)Treasury stock at cost,28,810 shares at june...$288K (0.00%↑ Y/Y)Total currentliabilities$12,111K (-2.28%↓ Y/Y)Non-current contingentconsideration$7,169K (-29.44%↓ Y/Y)Loan payable -non-current$1,620K (-1.16%↓ Y/Y)Non-current operating leaseliability$1,374K (135.27%↑ Y/Y)Non-current deferredresearch and development...$396K (-7.91%↓ Y/Y)Additional paid-in capital$376,154K (3.78%↑ Y/Y)Accumulated othercomprehensive loss$247K (-68.85%↓ Y/Y)Common stock, 0.001 parvalue 350,000,000...$45K (462.50%↑ Y/Y)Accrued expenses$6,418K (-28.82%↓ Y/Y)Contingent consideration,current portion$2,650K Deferred research anddevelopment tax...$1,210K (-9.90%↓ Y/Y)Accounts payable$984K (62.11%↑ Y/Y)Operating leaseliability-current portion$525K (185.78%↑ Y/Y)Accrued employeebenefits$290K (-61.79%↓ Y/Y)Loanspayable-current$34K (-39.29%↓ Y/Y)

Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc. (TOVX)